US Weighs In On High Court Biosimilars Battle
The federal government said the Federal Circuit got it wrong when it concluded that biosimilar makers can't give a 180-day notice of sales to rivals until a product is approved, telling...To view the full article, register now.
Already a subscriber? Click here to view full article